Cell Line Development Market Forecast, Trends To 2022: Grand View Research, Inc.

Cell Line Development Market To Reach $6.24 Billion By2022Global cell line development market size is expected to reach USD 6.24 billion by 2022,according to a new report by Grand View Research, Inc. The Increasing demand for monoclonalantibodies and patent expiration of blockbuster biologics are expected to drive the cell linedevelopment industry over the forecast period.Increasing prevalence of autoimmune diseases and cancer are likely to increase the demand foraccurate and cost effective treatment options which is expected to render a positive impact onmarket growth. In addition, improving healthcare infrastructure, economic development andfavorable government initiatives promoting the growth of the biotechnology industry are factorscontributing towards the growth of the cell line development market.Ongoing R&D for stable & authentic cell lines and the introduction of technologically advancedprocesses such as single use bioreactor and micro bioreactor for large scale bioproduction arefurther expected to provide this market with lucrative future growth opportunities.View summary of this report @ http://www.grandviewresearch.com/industry-analysis/cellline-development-market

U.S. cell line development market, by type, 2012-2022 (USD Million)Table of ContentChapter 1. Methodology and Scope1.1. Research methodology1.2. Research scope &assumption1.3. List of data sourcesChapter 2. Executive Summary2.1. Cell Line Development- Industry Snapshot and Key Buying Criteria, 2012 -2022Chapter 3. Cell Line Development Industry Outlook3.1. Cell line development market segmentation3.2. Cell line development market size and growth prospects, 2012 - 20223.3. Cell line development market dynamics3.3.1. Market driver analysis3.3.2. Market restraint analysis3.4. Key opportunities prioritized3.5. Industry Analysis - Porter's3.6. Cell line development competitive landscape, 2014

3.6.1. Company market share analysis, 20143.6.2. Market position analysis, 2014 (based on products, regional presence andstrategic initiatives)3.7. Cell line development market PESTEL analysis, 2014Chapter 4. Cell Line Development Product Outlook4.1. Cell line development market share by product, 2014 & 20224.2. Reagents and media4.2.1. Reagents and media market estimates and forecasts, 2012 – 2022 (USDmillion)4.3. Equipments4.3.1. Equipments market estimates and forecasts, 2012 – 2022 (USD million)4.3.2. Incubators4.3.2.1. Incubators market estimates and forecasts, 2012 – 2022 (USD million)4.3.3. Centrifuges4.3.3.1. Centrifuges market estimates and forecasts, 2012 – 2022 (USD million)4.3.4. Bioreactors4.3.4.1. Bioreactors market estimates and forecasts, 2012 – 2022 (USD million)4.3.5. Storage equipment4.3.5.1. Storage equipment market estimates and forecasts, 2012 – 2022 (USDmillion)4.3.6. Microscopes4.3.6.1. Microscopes market estimates and forecasts, 2012 – 2022 (USDmillion)4.4. Accessories and consumables4.4.1. Accessories and consumables market estimates and forecasts, 2012 – 2022(USD million)Chapter 5. Cell Line Development Source Outlook5.1. Cell line development market share by source, 2014 & 20225.2. Mammalian5.2.1. Mammalian market estimates and forecasts, 2012 – 2022 (USD million)5.3. Non mammalian5.3.1. Non mammalian market estimates and forecasts, 2012 – 2022 (USD million)5.3.2. Insects5.3.2.1. Insects market estimates and forecasts, 2012 – 2022 (USD million)5.3.3. Amphibians5.3.3.1. Amphibians market estimates and forecasts, 2012 – 2022 (USD million)Chapter 6. Cell Line Development Type Of Cell Lines Outlook6.1. Cell line development market share, by type of cell lines, 2014 & 2022

6.2. Recombinant cell lines6.2.1. Recombinant cell lines market estimates and forecasts, 2012 – 2022 (USDmillion)6.3. Hybridomas6.3.1. Hybridomas market estimates and forecasts, 2012 – 2022 (USD million)6.4. Continuous cell lines6.3.1. Continuous cell lines market estimates and forecasts, 2012 – 2022 (USDmillion)6.5. Primary cell lines6.5.1. Primary cell lines market estimates and forecasts, 2012 – 2022 (USDmillion)Chapter 7. Cell Line Development Application Outlook7.1. Cell line development market share, by application, 2014 & 20227.2. Bioproduction7.2.1. Bioproduction market estimates and forecasts, 2012 – 2022 (USD million)7.3. Drug discovery7.3.1. Drug discovery market estimates and forecasts, 2012 – 2022 (USD million)7.4. Toxicity testing7.4.1. Toxicity testing market estimates and forecasts, 2012 – 2022 (USD million)7.5. Vaccines7.5.1. Vaccines market estimates and forecasts, 2012 – 2022 (USD million)7.6. Tissue engineering7.6.1. Tissue engineering market estimates and forecasts, 2012 – 2022 (USDmillion)7.7. Others7.7.1. Others market estimates and forecasts, 2012 – 2022 (USD million)Chapter 8. Cell Line Development Regional Outlook8.1. Cell line development market share, by region, 2014 & 20228.2. North America8.2.1. North America market, by product, 2012 – 2022 (USD million)8.2.1.1. U.S.8.2.1.1.1. Market estimates and forecasts, 2014 - 20228.2.1.2. Canada8.2.1.2.1. Market estimates and forecasts, 2014 - 20228.2.2. North America market, by source, 2012 – 2022 (USD million)8.2.2.1. U.S.8.2.2.1.1. Market estimates and forecasts, 2014 - 20228.2.2.2. Canada

8.2.2.2.1. Market estimates and forecasts, 2014 – 20228.2.3. North America market, by type of cell lines, 2012 – 2022 (USD million)8.2.3.1. U.S.8.2.3.1.1. Market estimates and forecasts, 2014 - 20228.2.3.2. Canada8.2.3.2.1. Market estimates and forecasts, 2014 – 20228.2.4. North America market, by application, 2012 – 2022 (USD million)8.2.4.1. U.S.8.2.4.1.1. Market estimates and forecasts, 2014 - 20228.2.4.2. Canada8.2.4.2.1. Market estimates and forecasts, 2014 - 20228.3. Europe8.3.1. Europe market, by product, 2012 – 2022 (USD million)8.3.1.1. UK8.3.1.1.1. Market estimates and forecasts, 2014 - 20228.3.1.2. Germany8.3.1.2.1. Market estimates and forecasts, 2014 - 20228.3.2. Europe market, by source, 2012 – 2022 (USD million)8.3.2.1. UK8.3.2.1.1. Market estimates and forecasts, 2014 - 20228.3.2.2. Germany8.3.2.2.1. Market estimates and forecasts, 2014 – 20228.3.3. Europe market, by type of cell lines, 2012 – 2022 (USD million)8.3.3.1. UK8.3.3.1.1. Market estimates and forecasts, 2014 - 20228.3.3.2. Germany8.3.3.2.1. Market estimates and forecasts, 2014 – 20228.3.4. Europe market, by application, 2012 – 2022 (USD million)8.3.4.1. UK8.3.4.1.1. Market estimates and forecasts, 2014 - 20228.3.4.2. Germany8.3.4.2.1. Market estimates and forecasts, 2014 – 20228.4. Asia Pacific8.4.1. Asia Pacific market, by product, 2012 – 2022 (USD million)8.4.1.1. Japan8.4.1.1.1. Market estimates and forecasts, 2014 - 20228.4.1.2. China8.4.1.2.1. Market estimates and forecasts, 2014 – 2022

8.4.1.3. India8.4.1.3.1. Market estimates and forecasts, 2014 – 20228.4.2. Asia Pacific market, by source, 2012 – 2022 (USD million)8.4.2.1. Japan8.4.2.1.1. Market estimates and forecasts, 2014 - 20228.4.2.2. China8.4.2.2.1. Market estimates and forecasts, 2014 – 20228.4.2.3. India8.4.2.3.1. Market estimates and forecasts, 2014 – 20228.4.3. Asia Pacific market, by type of cell lines, 2012 – 2022 (USD million)8.4.3.1. Japan8.4.3.1.1. Market estimates and forecasts, 2014 - 20228.4.3.2. China8.4.3.2.1. Market estimates and forecasts, 2014 – 20228.4.3.3. India8.4.3.3.1. Market estimates and forecasts, 2014 – 20228.4.4. Asia Pacific market,, by application, 2012 – 2022 (USD million)8.4.4.1. Japan8.4.4.1.1. Market estimates and forecasts, 2014 - 20228.4.4.2. China8.4.4.2.1. Market estimates and forecasts, 2014 – 20228.4.4.3. India8.4.4.3.1. Market estimates and forecasts, 2014 – 20228.5. Latin America8.5.1. Latin America market, by product, 2012 – 2022 (USD million)8.5.1.1. Mexico8.5.1.1.1. Market estimates and forecasts, 2014 - 20228.5.1.2. Brazil8.5.1.2.1. Market estimates and forecasts, 2014 - 20228.5.2. Latin America market, by source, 2012 – 2022 (USD million)8.5.2.1. Mexico8.5.2.1.1. Market estimates and forecasts, 2014 - 20228.5.2.2. Brazil8.5.2.2.1. Market estimates and forecasts, 2014 – 20228.5.3. Latin America market, by type of cell lines, 2012 – 2022 (USD million)8.5.3.1. Mexico8.5.3.1.1. Market estimates and forecasts, 2014 - 20228.5.3.2. Brazil

8.5.3.2.1. Market estimates and forecasts, 2014 – 20228.5.4. Latin America market, by application, 2012 – 2022 (USD million)8.5.4.1. Mexico8.5.4.1.1. Market estimates and forecasts, 2014 - 20228.5.4.2. Brazil8.5.4.2.1. Market estimates and forecasts, 2014 – 20228.6. MEA8.6.1. MEA market, by product, 2012 – 2022 (USD million)8.6.1.1. South Africa8.6.1.1.1. Market estimates and forecasts, 2014 - 20228.6.2. MEA market, by source, 2012 – 2022 (USD million)8.6.2.1. South Africa8.6.2.1.1. Market estimates and forecasts, 2014 – 20228.6.3. MEA market, by type of cell lines, 2012 – 2022 (USD million)8.6.3.1. South Africa8.6.3.1.1. Market estimates and forecasts, 2014 – 20228.6.4. MEA market, by application, 2012 – 2022 (USD million)8.6.4.1. South Africa8.6.4.1.1. Market estimates and forecasts, 2014 – 2022Chapter 9. Competitive Landscape9.1. GE Healthcare9.1.1. Company Overview9.1.2. Financial Performance9.1.3. Product Benchmarking9.1.4. Strategic Initiatives9.2. Thermo Fisher Scientific Inc. (Lifetechnologies)9.2.1. Company Overview9.2.2. Financial Performance9.2.3. Product Benchmarking9.2.4. Strategic Initiatives9.3. European Collection of Cell Cultures9.3.1. Company Overview9.3.2. Financial Performance9.3.3. Product Benchmarking9.3.4. Strategic Initiatives9.4. Lonza Group AG9.4.1. Company Overview9.4.2. Financial Performance

9.4.3. Product Benchmarking9.4.4. Strategic Initiatives9.5. Sigma Aldrich Corporation9.5.1. Company Overview9.5.2. Financial Performance9.5.3. Product Benchmarking9.5.4. Strategic Initiatives9.6. WuXi AppTec9.6.1. Company Overview9.6.2. Financial Performance9.6.3. Product Benchmarking9.6.4. Strategic Initiatives9.7. American Type Culture Collection9.7.1. Company Overview9.7.2. Financial Performance9.7.3. Product Benchmarking9.7.4. Strategic Initiatives9.8. Sartorius AG9.8.1. Company Overview9.8.2. Financial Performance9.8.3. Product Benchmarking9.8.4. Strategic Initiatives9.9. Corning Inc.9.9.1. Company Overview9.9.2. Financial Performance9.9.3. Product Benchmarking9.9.4. Strategic Initiatives9.10. Selexis AG9.10.1. Company Overview9.10.2. Financial Performance9.10.3. Product Benchmarking9.10.4. Strategic Initiatives9.11. Vista Biological Co9.11.1. Company Overview9.11.2. Financial Performance9.11.3. Product Benchmarking9.11.4. Strategic Initiatives9.12. Eubiologics

9.12.1. Company Overview9.12.2. Financial Performance9.12.3. Product Benchmarking9.12.4. Strategic Initiatives9.13. Paragon Bioservices9.13.1. Company Overview9.13.2. Financial Performance9.13.3. Product Benchmarking9.13.4. Strategic Initiatives9.14. Cobra9.14.1. Company Overview9.14.2. Financial Performance9.14.3. Product Benchmarking9.14.4. Strategic Initiatives9.15. Gallus Biopharma9.15.1. Company Overview9.15.2. Financial Performance9.15.3. Product Benchmarking9.15.4. Strategic Initiatives9.16. Samsung Biologic9.16.1. Company Overview9.16.2. Financial Performance9.16.3. Product Benchmarking9.16.4. Strategic Initiatives9.17. Naeja9.17.1. Company Overview9.17.2. Financial Performance9.17.3. Product Benchmarking9.17.4. Strategic Initiatives9.18. Aragen Bioscience9.18.1. Company Overview9.18.2. Financial Performance9.18.3. Product Benchmarking9.18.4. Strategic Initiatives9.19. GVK BIO9.19.1. Company Overview9.19.2. Financial Performance9.19.3. Product Benchmarking

9.19.4. Strategic Initiatives9.20. PCT9.20.1. Company Overview9.20.2. Financial Performance9.20.3. Product Benchmarking9.20.4. Strategic Initiatives9.21. Apath9.21.1. Company Overview9.21.2. Financial Performance9.21.3. Product Benchmarking9.21.4. Strategic Initiatives9.22. Cell for cure9.22.1. Company Overview9.22.2. Financial Performance9.22.3. Product Benchmarking9.22.4. Strategic Initiatives9.23. TRL9.23.1. Company Overview9.23.2. Financial Performance9.23.3. Product Benchmarking9.23.4. Strategic Initiatives9.24. Episteme9.24.1. Company Overview9.24.2. Financial Performance9.24.3. Product Benchmarking9.24.4. Strategic Initiatives9.25. Catalent9.25.1. Company Overview9.25.2. Financial Performance9.25.3. Product Benchmarking9.25.4. Strategic Initiatives9.26. Bioceros9.26.1. Company Overview9.26.2. Financial Performance9.26.3. Product Benchmarking9.26.4. Strategic Initiatives9.27. Antitope9.27.1. Company Overview

9.27.2. Financial Performance9.27.3. Product Benchmarking9.27.4. Strategic Initiatives9.28. Promocell9.28.1. Company Overview9.28.2. Financial Performance9.28.3. Product Benchmarking9.28.4. Strategic Initiatives9.29. Cyagen9.29.1. Company Overview9.29.2. Financial Performance9.29.3. Product Benchmarking9.29.4. Strategic InitiativesBrowse full report @ http://www.grandviewresearch.com/industry-analysis/cell-linedevelopment-marketList of TablesTABLE 1 Cell Line Development - Industry Snapshot & Key Buying Criteria, 2012 - 2022TABLE 2 Global cell line development market, by product, 2012 - 2022 (USD Million)TABLE 3 Global cell line development market, by source, 2012 - 2022 (USD Million)TABLE 4 Global cell line development market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 5 Global cell line development market, by application, 2012 - 2022 (USD Million)TABLE 6 Global cell line development market, by region, 2012 - 2022 (USD Million)TABLE 7 Cell line development - Key market driver analysisTABLE 8 Global cancer incidences, 2012TABLE 9 North America cancer incidences in 2012TABLE 10 Europe cancer incidences, 2012TABLE 11 Asia cancer incidences, 2012TABLE 12 Africa cancer incidences, 2012TABLE 13 Australia and New Zealand cancer incidences in 2012TABLE 14 Cell line development - Key market restraint analysisTABLE 15 North America market, by product, 2012 - 2022 (USD Million)TABLE 16 North America market, by equipment, 2012 - 2022 (USD Million)TABLE 17 North America cell line development market, by source, 2012 - 2022 (USD Million)TABLE 18 North America market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 19 North America market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 20 North America market, by application, 2012 - 2022 (USD Million)TABLE 21 U.S. cell line development market, by product, 2012 - 2022 (USD Million)

TABLE 22 U.S cell line development market, by equipment, 2012 - 2022 (USD Million)TABLE 23 U.S. cell line development market, by source, 2012 - 2022 (USD Million)TABLE 24 U.S. market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 25 U.S. market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 26 U.S. market, by application, 2012 - 2022 (USD Million)TABLE 27 Canada market, by product, 2012 - 2022 (USD Million)TABLE 28 Canada market, by equipment, 2012 - 2022 (USD Million)TABLE 29 Canada market, by source, 2012 - 2022 (USD Million)TABLE 30 Canada market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 31 Canada market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 32 Canada market, by application, 2012 - 2022 (USD Million)TABLE 33 Europe market, by product, 2012 - 2022 (USD Million)TABLE 34 Europe market, by equipment, 2012 - 2022 (USD Million)TABLE 35 Europe market, by source, 2012 - 2022 (USD Million)TABLE 36 Europe market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 37 Europe market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 38 Europe market, by application, 2012 - 2022 (USD Million)TABLE 39 UK market, by product, 2012 - 2022 (USD Million)TABLE 40 UK market, by equipment, 2012 - 2022 (USD Million)TABLE 41 UK market, by source, 2012 - 2022 (USD Million)TABLE 42 UK market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 43 UK market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 44 UK market, by application, 2012 - 2022 (USD Million)TABLE 45 Germany market, by product, 2012 - 2022 (USD Million)TABLE 46 Germany market, by equipment, 2012 - 2022 (USD Million)TABLE 47 Germany market, by source, 2012 - 2022 (USD Million)TABLE 48 Germany market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 49 Germany market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 50 Germany market, by application, 2012 - 2022 (USD Million)TABLE 51 Asia Pacific market, by product, 2012 - 2022 (USD Million)TABLE 52 Asia Pacific market, by equipment, 2012 - 2022 (USD Million)TABLE 53 Asia Pacific market, by source, 2012 - 2022 (USD Million)TABLE 54 Asia Pacific market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 55 Asia Pacific market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 56 Asia Pacific market, by application, 2012 - 2022 (USD Million)TABLE 57 Japan market, by product, 2012 - 2022 (USD Million)TABLE 58 Japan market, by equipment, 2012 - 2022 (USD Million)TABLE 59 Japan market, by source, 2012 - 2022 (USD Million)TABLE 60 Japan market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 61 Japan market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 62 Japan market, by application, 2012 - 2022 (USD Million)TABLE 63 China market, by product, 2012 - 2022 (USD Million)TABLE 64 China market, by equipment, 2012 - 2022 (USD Million)

TABLE 65 China market, by source, 2012 - 2022 (USD Million)TABLE 66 China market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 67 China market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 68 China market, by application, 2012 - 2022 (USD Million)TABLE 69 India market, by product, 2012 - 2022 (USD Million)TABLE 70 India market, by equipment, 2012 - 2022 (USD Million)TABLE 71 India market, by source, 2012 - 2022 (USD Million)TABLE 72 India market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 73 India market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 74 India market, by application, 2012 - 2022 (USD Million)TABLE 75 Latin America market, by product, 2012 - 2022 (USD Million)TABLE 76 Latin America market, by equipment, 2012 - 2022 (USD Million)TABLE 77 Latin America market, by source, 2012 - 2022 (USD Million)TABLE 78 Latin America market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 79 Latin America market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 80 Latin America market, by application, 2012 - 2022 (USD Million)TABLE 81 Brazil market, by product, 2012 - 2022 (USD Million)TABLE 82 Brazil market, by equipment, 2012 - 2022 (USD Million)TABLE 83 Brazil market, by source, 2012 - 2022 (USD Million)TABLE 84 Brazil market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 85 Brazil market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 86 Brazil market, by application, 2012 - 2022 (USD Million)TABLE 87 Mexico market, by product, 2012 - 2022 (USD Million)TABLE 88 Mexico market, by equipment, 2012 - 2022 (USD Million)TABLE 89 Mexico market, by source, 2012 - 2022 (USD Million)TABLE 90 Mexico market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 91 Mexico market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 92 Mexico market, by application, 2012 - 2022 (USD Million)TABLE 93 MEA market, by product, 2012 - 2022 (USD Million)TABLE 94 MEA market, by equipment, 2012 - 2022 (USD Million)TABLE 95 MEA market, by source, 2012 - 2022 (USD Million)TABLE 96 MEA market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 97 MEA market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 98 MEA market, by application, 2012 - 2022 (USD Million)TABLE 99 South Africa market, by product, 2012 - 2022 (USD Million)TABLE 100 South Africa market, by equipment, 2012 - 2022 (USD Million)TABLE 101 South Africa market, by source, 2012 - 2022 (USD Million)TABLE 102 South Africa market, by non mammalian source, 2012 - 2022 (USD Million)TABLE 103 South Africa market, by type of cell lines, 2012 - 2022 (USD Million)TABLE 104 South Africa market, by application, 2012 - 2022 (USD Million)For More Information visit http://www.grandviewresearch.com/industry-analysis/cell-linedevelopment-market

For the purpose of this study, Grand View Research has segmented the global cell linedevelopment market on the basis of product, source, type of cell line, application and region:Global Cell Line Development Product Outlook (Revenue, USD Million, 2012– 2022)Reagents and mediaEquipment• Incubators• Centrifuges• Bioreactors• Storage equipment• MicroscopesAccessories and consumablesGlobal Cell Line Development Source Outlook (Revenue, USD Million, 2012– 2022)ooMammalianNon mammalian• Insects• AmphibiansGlobal Cell Line Development Type Of Cell Line Outlook (Revenue, USD Million, 2012–2022)Recombinant cell linesHybridomasContinuous cell linePrimary cell linesGlobal Cell Line Development Application Outlook (Revenue, USD Million, 2012– 2022)BioproductionDrug discoveryToxicity testingTissue engineeringResearchCell Line Development Regional Outlook (Revenue, USD Billion, 2014 – 2022)North America• U.S.• CanadaEurope• Germany• UK

Asia Pacific• China• Japan• IndiaLatin America• Mexico• BrazilMEA• South AfricaBrowse All Reports of this category @http://www.grandviewresearch.com/industry/clinical-diagnosticsAbout Grand View ResearchGrand View Research, Inc. is a market research and consulting company that provides off-theshelf,customized research reports and consulting services. To help clients make informedbusiness decisions, we offer market intelligence studies ensuring relevant and fact-based researchacross a range of industries, from technology to chemicals, materials and energy. With a deepseatedunderstanding of varied business environments, Grand View Research provides strategicobjective insights.Contact:Sherry JamesCorporate Sales Specialist, U.S.A.Grand View Research, Inc.United StatesPhone: 1-415-349-0058Toll Free: 1-888-202-9519Email: sales@grandviewresearch.comWebsite: Grand View ResearchBlog Site: http://www.divog.org/